Review Article

Irisin: A Promising Target for Ischemia-Reperfusion Injury Therapy

Yani Wang,1,2 Huibin Liu,2,3 Na Sun,1,2 Jing Li,2,3 Xiang Peng,1,2 Ying Jia,1,2 Jason Karch,4 Bo Yu,1,2 Xander H. T. Wehrens,5 and Jinwei Tian1,2

1Department of Cardiology, The Second Affiliated Hospital of Harbin Medical University, Harbin 150086, China
2The Key Laboratory of Myocardial Ischemia, Harbin Medical University, Ministry of Education, Harbin 150086, China
3Department of Clinical Pharmacy, The Second Affiliated Hospital of Harbin Medical University, Harbin 150086, China
4Cardiovascular Research Institute, Department of Molecular Physiology & Biophysics, Baylor College of Medicine, Houston, TX 77030, USA
5Cardiovascular Research Institute, Departments of Molecular Physiology & Biophysics, Medicine, Neuroscience, Pediatrics, And Center for Space Medicine, Baylor College of Medicine, Houston, TX 77030, USA

Correspondence should be addressed to Bo Yu; dryu_hmu@163.com and Jinwei Tian; tianjinweidr2009@163.com

Received 2 September 2021; Revised 8 October 2021; Accepted 18 October 2021; Published 29 October 2021

Academic Editor: Yuli Huang

Copyright © 2021 Yani Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Ischemia-reperfusion injury (IRI) is defined as the total combined damage that occurs during a period of ischemia and following the recovery of blood flow. Oxidative stress, mitochondrial dysfunction, and an inflammatory response are factors contributing to IRI-related damage that can each result in cell death. Irisin is a polypeptide that is proteolytically cleaved from the extracellular domain of fibronectin type III domain-containing protein 5 (FNDC5). Irisin acts as a myokine that potentially mediates beneficial effects of exercise by reducing oxidative stress, improving mitochondrial fitness, and suppressing inflammation. The existing literature also suggests a possible link between irisin and IRI, involving mechanisms similar to those associated with exercise. This article will review the pathogenesis of IRI and the potential benefits and current limitations of irisin as a therapeutic strategy for IRI, while highlighting the mechanistic correlations between irisin and IRI.

1. Introduction

Whereas improvements in pharmacological treatments (e.g., thrombolytic drugs) and interventional therapies (e.g., percutaneous transluminal coronary angioplasty) can recover blood perfusion in ischemic heart tissue, the recovery of blood flow (known as reperfusion) can promote metabolic dysfunction associated with cell death. Ischemia-reperfusion injury (IRI) occurs when the blood supply is restored after a temporary loss of oxygen (O₂) supply (known as ischemia) [1]. As a common pathological phenomenon, IRI occurs in the context of many pathological conditions including acute coronary syndrome, hypovolemic shock, ischemic stroke, and sickle cell disease (SCD). IRI associated with a significant amount of tissue or organ damage can also impact remote organs that were not ischemic during the initial injury [2]. It is currently well established that IRI involves multiple cellular mechanisms, including oxidative stress, mitochondrial dysfunction, and an inflammatory response. While many mechanisms contribute to the pathogenesis of IRI, we will focus on these 3 major pathways and then highlight the specific roles played by irisin, a polypeptide that is proteolytically cleaved from the extracellular domain of fibronectin type III domain-containing protein 5 (FNDC5). Irisin acts as a myokine that is hypothesized to be protective against IRI as it reduces oxidative stress, improves mitochondrial dysfunction, and suppresses inflammation.

2. Mechanistic Insights into the Pathogenesis of IRI

2.1. Oxidative Stress in IRI. In 1985, “oxidative stress” was first introduced by Dr. Helmut Sies as a concept in redox
biology and medicine. This term was defined as “An imbalance between oxidants and antioxidants in favor of the oxidants, leading to a disruption of redox signaling and control and/or molecular damage” [3]. Oxidative stress can be divided into enzymic and nonenzymic stress depending on its source, both of which occur as part of the IRI response. Enzymic oxidative stress is generated by the xanthine oxidase (XO) system, the nicotinamide adenine dinucleotide phosphate (NADPH) oxidase (NOX) system, and the uncoupled nitric oxide synthase (NOS) system, among others. Nonenzymic oxidative stress primarily consists of hemoglobin [4]. Oxidative stress is a vital driving force contributing to the acceleration of various pathological cellular processes during IRI (see Figure 1).
2.1.1. Enzymic Systems Involving Oxidative Stress. As a significant component of the XO system, XO and its precursor xanthine dehydrogenase (XD) account for 10% and 90% with existent forms in vivo, respectively [5]. Dysfunction of membrane channels induced by the lack of adenosine triphosphate (ATP) leads to abnormal calcium influx during ischemia, which activates calcium-dependent proteases and further promotes XD conversion to XO. Meanwhile, the declining partial oxygen pressure results in further ATP degradation, which causes accumulation of hypoxanthine as the substrate for XO. Following restoration of the blood flow during reperfusion, O₂ floods into the ischemic area. As the final electron acceptor, O₂ promotes the transformation of hypoxanthine into uric acid though XO. During this catalysis, vast quantities of superoxide (O₂⁻), hydroxyl radical (·OH), and hydrogen peroxide (H₂O₂)—all types of reactive oxygen (ROS)—are generated and contribute to oxidative stress [6, 7].

In regard to the NOX system, NOX spans two heme moieties, and the cytoplasmic carboxy terminus of NOX has binding domains for NADPH and flavin adenine dinucleotide (FAD) [8]. In this system, O₂ is the final electron acceptor via the heme groups, FAD and NADPH [9, 10]. During electron transfer, NOX produces large amounts of O₂•⁻, which leads to spontaneous transformation of O₂•⁻ into H₂O₂ in vivo, the latter having a direct cytotoxic effect [11, 12]. Additionally, H₂O₂ causes cytotoxicity indirectly when metal ions (e.g., ferrous) exist, leading to the production of the highly reactive molecule ·OH via the Fenton reaction [13]. During ischemia, activated hypoxia-inducible factor-1α (HIF-1α) activates NOX, which further induces vast production of O₂•⁻, H₂O₂, and ·OH to trigger oxidative stress. In turn, oxidative stress also increases the expression of HIF-1α [4]. Moreover, cytokines and other bioactivator molecules are released in large quantities and also activate NOX, thereby further contributing to oxidative stress [2, 14, 15].

NOS is one of dominant oxidative stress factors in cardiovascular and metabolic diseases [16]. Using cofactor tetrahydrobiopterin (BH₄), NOS catalyzes O₂ and L-arginine (L-Arg) into L-citrulline (L-Cit) and nitric oxide (NO). NO has vasodilative and anti-inflammatory effects [17]. During IRI, oxidative stress or catabolism results in a decreased BH₄ content, which induces uncoupling of NOS. As a result, the production of O₂•⁻ increases. While the generation of NO decreases, leading to increased oxidative stress [4].

2.1.2. Nonenzymic System Involving Oxidative Stress. The pathogenesis of SCD involves mutant β-globin chains initiating the polymerization of hemoglobin S and sickling of erythrocytes [18]. Notably, erythrocyte abnormalities in SCD mainly manifest themselves periodical as hemolytic anemia and microvascular occlusion, causing end-organ IRI. Sickle red blood cells (sRBCs) are prone to damage because of their deformation and osmotic fragility. Damaged sRBCs adhere to endothelial cells, resulting in adhesion-mediated vasoocclusion and impaired blood flow followed by accumulation of oxygen free radical and ROS [18, 19]. During the hemolytic phase, the release of free hemoglobin derived from plasma may scavenge NO, and inhibit NO-mediated provasodilative and antioxidative stress effects. Hence, nonenzymic oxidative stress participates in the pathogenesis of IRI and in end-organ damage [18, 19].

2.2. Mitochondrial Dysfunction in IRI. Mitochondria dysfunction is a pivotal mediator of IRI [20]. There are several associations between IRI and mitochondrial dysfunction, including electron transport chain- (ETC-) mediated ROS generation and ROS-induced mitochondrial permeability transition pore (mPTP) opening, which all contribute to the induction of the mitochondrial quality control pathway (see Figure 1).

2.2.1. Mitochondrial Oxidative Stress and mPTP Opening. Mitochondria are a major source of ROS generation, in which complex I and complex III, the principal components of the ETC, are of the main contributors to mitochondrial ROS (mtROS) production. Complex I interacts with its metabolic substrates, releasing 2 electrons to the coenzyme Q (CoQ) reduction site by cofactors flavin mononucleotide (FMN), followed by reduction of CoQ to CoQH₂ and the simultaneous release of 2 electrons. In the mitochondrial ECT, both the FMN domain and the CoQ binding site are sites of superoxide production [21]. In the highly reduced state of the CoQ pool, electrons from CoQH₂ are forced to return to complex I, a process known as reverse electron transport (RET) [22]. The maximum production of superoxide in RET is much faster than the maximum rate of ETC. Therefore, complex I-related RET is deemed to be the main source of superoxide production during IRI [23]. Complex III participates in ubiquitin oxidation and cytochrome c reduction in the Q cycle, which produces vast amounts of superoxide by mediating the reaction of ubisemiquinone bound to the CoQ site and O₂ [24]. The superoxide in both of these sources convert into H₂O₂ during IRI, which in turn causes mtROS accumulation in large quantities and contributes to mitochondrial dysfunction [25].

Continuous ischemia may trigger cell death and tissue injury depending on the duration of the ischemic period. However, in some cases, the majority of damage actually occurs during the reperfusion phase [23]. The initial few minutes of reperfusion are crucial for the severity of IRI: soon after the start of reperfusion there is a burst of mtROS generation [20, 23]. Ischemia-induced damage alters the metabolic supply and oxygen utilization, leading to the formation of intracellular acidification, triggering intracellular and mitochondrial calcium overload, and mPTP opening subsequently [20, 26, 27]. During reperfusion, the large increase in oxidative stress further sensitizes the mPTP sensitivity to calcium. Thus, the majority of the mPTP opening occurs upon reperfusion [25]. Following mPTP opening, water and solutes will flow freely into the mitochondrial matrix, leading to mitochondrial swelling, loss of the mitochondrial membrane potential, and release of intermembrane space proteins (e.g., cytochrome c and apoptosis-inducing factor). Eventually, caspase-dependent or caspase-independent cell death will occur depending on the overall severity of mitochondrial dysfunction that has occurred within the individual myocyte [28, 29].
2.2.2. Response of Mitochondrial Quality Control. Mitochondrial quality control is a dynamic process that includes fission, fusion, mitophagy, and biogenesis. During oxidative stress, dynamin-related protein 1 (Drp1) translocates to damaged mitochondrial exterior membranes via actin and microtubule-mediated transport mechanisms, and with Drp1 receptors on the outer mitochondrial membrane including mitochondrial fission protein 1 (Fis1) [30–32]. Following the interaction of Drp1 with its receptors, mitochondria appear to constrict and dissociate leading to mitochondrial fission [33, 34]. Moreover, optic atrophy 1 (Opal) mediates the fusion between the damaged mitochondria and the outer mitochondrial membranes of normal mitochondria in an apparent effort to rescue the abnormal mitochondria by a process known as mitochondrial fusion [35, 36]. In most cases, mitophagy occurs following fission and is degraded by mitophagic proteins to maintain overall mitochondrial integrity. The degraded components will be reused for supplying proteins and lipids to potentially promote the growth of new mitochondria, a process known as mitochondrial biogenesis [37]. Mitophagy and mitochondrial biogenesis are two processes that contribute to the maintenance of mitochondrial content and metabolism.

Zhou et al. [38] found that an ischemia-related cascade can contribute to the triggering of fatal mitochondrial fission in endothelial cells. During reperfusion, Drp1 translocates to the mitochondrial exterior membrane and mediates mitochondrial fission [39, 40]. Additionally, the function of Opal is interrupted in a Bax- and Bak-dependent manner, hindering mitochondrial membrane fusion in cardiomyocytes [41, 42]. Together, these changes in mitochondrial dynamics are closely related to heart IRI. Alternatively, Parkin mediates the ubiquitination of Drp1, which reduces mitochondrial fission, as part of a mitochondrial quality control system that is protective against IRI [43]. Indeed, moderate mitophagy increases the survival advantage of cardiomyocytes following IRI; however, overactivation of mitophagy can be detrimental for the cell [44]. There is evidence suggesting that autophagy overactivation induces cortical neural cell injury following cerebral IRI [45]. Likewise, damage-derived overactivation of autophagy occurs in intestinal and myocardial IRI [46, 47]. Therefore, the aforementioned molecules involved in mitochondrial dynamics and quality control are highly relevant to IRI.

2.3. Inflammatory Response in IRI. Metabolic disturbance-induced inflammatory responses promote injury of cells and tissues during ischemia and hypoxia, while ischemia-related metabolic disturbances further translate into an excess innate immune response causing deterioration of injury and organ failure following reperfusion (see Figure 1).

2.3.1. Initial Activation of Inflammatory Response. Neutrophils are regarded as major participants in cellular injury events caused by IRI [48, 49]. The formation of a directional chemotactic gradient and the involvement of chemokines mediate neutrophil adherence, exosmosis, and directional migration [50, 51]. Liver injury after ischemia and reperfusion is gradually induced by neutrophil activation and adherence within the liver sinusoidal vasculature, neutrophil migration to the liver parenchyma, and the release of granule enzymes [52, 53]. In terms of hepatic IRI, oxidative stress induces injury within cells directly leading to the release of "damage-associated molecular patterns" (DAMPs), promoting production of inflammatory factors by Kupffer cells [50]. As a ligand, DAMPs combine with toll-like receptors which are upregulated on the surface of neutrophils and stimulate the production of chemokines to initiate the sterile inflammation [50, 54]. The initial activation of a proinflammatory response during ischemia contributes to the subsequent injury that takes place during reperfusion [55].

2.3.2. Amplification of Inflammatory Cascades. The amplification of the inflammatory response during reperfusion is primarily related to the release of ROS and neutrophil granule enzymes. Neutrophils gather on and adhere to the surface of hepatocytes and subsequently appear fully degranulated subsequently, resulting in the release of several proteases [50]. The powerful proteolytic effect of elastase induces endothelial cell injury and organ damage [56]. The reaction between myeloperoxidase and H2O2 produces hypochlorous acid (HOCl) and hypochlorite (OCl-), which can contribute to IRI damage [57]. Ischemia-related metabolic disturbance impedes adenosine synthesis, leading to activation of neutrophil phagocytosis and an inflammatory response. During reperfusion, oxygen uptake by neutrophils increases and oxygen radicals accumulate in excess, causing an oxidative damage [58, 59]. Limiting neutrophil adhesion and production of superoxide mediated by the lack of adenosine alleviates IRI in liver and SCD [60–62]. Together, the initial activation of the immune reaction mediated by inflammatory mediators and cells, as well as the amplifying effect of inflammation mediated by the release of neutrophil protease and the oxidative stress, exacerbate IRI.

3. The Discovery and Characterization of Irisin

3.1. The Discovery of Irisin. Exercise has a protective effect on cardiovascular diseases and metabolic disorders [63]. The endocrine function of cardiac muscle and skeletal muscle promotes the synthesis and release of myokines when the muscle contracts, which is mediated by the transcriptional coactivator peroxisome proliferator-activated receptor- (PPAR-) c coactivator-1α (PGC1-α). In 1998, Puigserver et al. [64] discovered that the expression of PGC1-α in brown fat and striated muscle increases remarkably during cold exposure, exerting adaptive thermogenesis by inducing mitochondrial biosynthesis and coactivation of the function of PPAR-γ on the UCP1 promoter. In 2012, Bostrom et al. [65] demonstrated that PGC1-α causes muscle cells to secrete a molecule that mediates browning of subcutaneous white adipose, which regulates thermogenesis indirectly. Using gene expression arrays, this molecule was identified as FNDC5, a secreted PGC1-α-dependent protein [65]. Moreover, this research confirmed that recombinant FNDC5 could induce brown fat-like conversion of subcutaneous white adipose and accelerated energy expenditure. Subsequently, mass spectrometry uncovered an effective
splice product of FNDC5 secreted into the circulation. This exercise-related polypeptide consisting of 112 amino acids was named irisin [65]. In 2018, proteomics and mass spectrometry studies revealed that integrin αV/β5 acts as the functional receptor of irisin, providing potential targets for the mechanistic regulation of irisin [66]. This new exercise-related polypeptide irisin sparked great interest in the scientific community. As a potential connection between exercise and metabolic disorders, irisin opened a window of opportunity for improving existing treatment protocols and novel therapeutic strategies.

3.2. The Characterization of Irisin

3.2.1. Cytoprotection of Irisin. The source of irisin has been studied in Sprague-Dawley rats, which revealed that it is produced more in cardiac muscle than in skeletal muscle [67]. The biological effects and mechanisms of action of irisin in cardiac ischemia have been partly identified since its initial discovery [68, 69]. The protective role of irisin is related to its regulation of energy metabolism and fatty acid metabolism, but involves a heterogeneous effect in several cell types. Irisin promotes cardiac progenitor cell-related myocardial repair [70], improves endothelial dysfunction-induced abnormal vasomotor function [71], and affects macrophage-mediated host defense function [72] to realize a beneficial effect in multiple cardiac disorders. Furthermore, irisin is highly conserved across all mammalian species. The similarity of irisin in human and mouse reaches close to 100% [65]. The high level of conservation of irisin may be suggestive of its important roles in protecting against oxidative stress, mitochondrial dysfunction, and inflammation.

IRI triggers multiple programmed cell death pathways including necrosis, apoptosis, and autophagy, in which the first two are classic death patterns seen in IRI-related disorders and autophagy is an adaptive response to such stress states [73, 74]. Necrosis exerts highly immunostimulatory effects, and apoptosis induces autonomic cell death, both of which results in organ dysfunction [1]. Autophagy plays a beneficial role in IRI by inhibiting apoptosis and eliminating damaged mitochondria. The IRI-related cytoprotection of irisin involves antiapoptosis, proautophagy, and anti-inflammatory effects [75, 76]. Apoptosis has been identified as a main pathophysiological mechanism in myocardial IRI, which can be rescued by irisin’s induction to autophagy [74, 77]. Similar protective effects occur in hepatic IRI [78]. In the next chapter, we will discuss the mechanisms by which irisin protects against IRI in detail; however, there are some controversies in the field.

3.2.2. Controversies about the Effects of Irisin. A meta-analysis based on 741 studies showed that irisin concentrations in patients with coronary artery disease (CAD) are lower than those in healthy controls [79]. In advanced cases with CAD, the irisin concentrations are lower than those in the control group and milder cases [80]. Therefore, irisin has been proposed as a biomarker for monitoring the severity of CAD in patients [81]. However, the predictive value of irisin levels are paradoxical in cardiovascular diseases. Based on current research, higher irisin concentrations are correlated with an increased risk of acute coronary syndrome and adverse cardiovascular events [82, 83]. In acute heart failure, patients with higher circulating irisin levels had a higher mortality [84]. Interestingly, polymorphisms in the PGC1-α gene are related to an increased risk of hypertrophic cardiomyopathy [85]. Meanwhile, one study showed that a single-nucleotide polymorphism in the irisin gene may be a genetic risk factor for myocardial infarction. The rs3480 genotypes and rs726344 genotypes of the irisin gene are associated with hypertension, diabetes, and hyperlipidemia, demonstrating that both may confer an enhanced susceptibility to MI [86].

These seemingly contradictory effects of irisin might be due to variations of several factors, such as the type and intensity of exercise, the detecting methods and testing times, the baseline concentration of glucose, lipids, and inflammatory factors in vivo. In addition to variations in experimental design and techniques, irisin might exert both compensatory and reactive changes as part of the disease pathogenesis, which might explain such heterogeneity as well. On the one hand, the irisin abundance appears to be associated with the stage of disease development [82, 87]. Hence, we infer that higher irisin levels in the early stages exert a protective effect to inhibit myocardiocyte apoptosis and disease deterioration, but increase the risk of adverse events in advanced states. On the other hand, the dose-effect relationship of irisin plays a vital role in cardiac diseases [88]. Thus, studies probing the median effective dose and the median toxic dose of irisin are urgently needed in various cardiac diseases. Meanwhile, the clinical transformation of irisin should also take into account the adverse aspect with its higher energy expenditure [67, 89].

4. The Mechanistic Correlation between Irisin and IRI

Recently, the effects of irisin on antioxidative stress, mitochondrial protection, and anti-inflammatory signaling have been investigated. Strikingly, the main mechanisms and key molecules contributing to IRI correlate with the protective effects of irisin. In the following section, we will focus on the correlation between the effects of irisin and IRI in regard to oxidative stress, mitochondrial dysfunction, and inflammatory response (see Figure 2).

4.1. The Role of Irisin in Antioxidative Stress in IRI. Irisin has been shown to play a role in the antioxidative stress response. The balance between oxidase and antioxidase maintained by irisin may delay disease development to some extent. NOX mediates the production of ROS in a rat model of transverse aortic constriction (TAC). The accumulation of ROS has two types of impact, one is the uncoupling of NOS, which causes a decrease in NO production and an increase in ROS concentrations; the second one is activation of XO, which exacerbates oxidative stress and pressure overload-induced cardiac remodeling. Conversely, irisin was shown to inhibit the expression of NOX and XO in cardiac muscle of rats with TAC, and reverse the decline of glutathione.
peroxidases (GPxS) and superoxide dismutase 1 (SOD1) levels, thereby reducing the level of oxidative stress and damage [90]. Irisin also increases NOS expression and initiates NO generation in the context of obesity or vascular complications of diabetes [91, 92]. Under high-glucose or high-fat conditions, excessive NO interacts with superoxide to produce peroxynitrite. In contrast, irisin mitigates endothelial cell dysfunction and delays the progression of atherosclerosis by inhibiting NOS-mediated oxidative and nitrative stress [93, 94]. Changes in plasma irisin levels were shown to correlate with circulating nitrite and nitrate levels, suggesting that increased irisin secretion leads to a reduction in arterial stiffness due to NO production [91]. The abovementioned antioxidant targets of irisin can contribute to the reversal of pathological processes induced by IRI.

Oxidative stress is one of the important mechanisms in IRI, whereas irisin can play an antioxidative stress role that can ameliorate IRI in distant organs. In terms of antioxidant systems, irisin protects the heart from IRI in a dose-dependent manner by means of increasing SOD activity and concentrations to decrease total ROS generation in vivo [95, 96]. In peri-infarct brain tissue, the rising levels of superoxide anion, nitrotyrosine, and 4-hydroxy-2-

Figure 2: The mechanisms of irisin in ischemia-reperfusion injury in various organs. Ischemia-reperfusion injury occurs in various organs, including the cerebrum, lung, heart, liver, kidney, and intestines. The pathogenesis of ischemia-reperfusion injury includes oxidative stress, mitochondrial dysfunction, an inflammatory response, and other pathways. The roles of irisin in various mechanistic pathways underlying ischemia-reperfusion injury have been studied in different organs. AMPK: adenosine 5′-monophosphate-activated protein kinase; ERK: extracellular-regulated protein kinases; ER stress: endoplasmic reticulum stress; MMP: mitochondrial membrane potential; mPTP: mitochondrial permeability transition pore; mtROS: mitochondrial reactive oxygen; NLRP3: NOD-like receptor family, pyrin domain-containing 3.
between irisin and NOS needs further clarification [94]. With regard to hemodynamic damage, irisin levels have been negatively correlated with the hemodynamic severity in pulmonary arterial hypertension [101]. Additionally, irisin can promote the proliferation of endothelial cells after flap revascularization to counteract reperfusion injury [102].

Overall, enzymic and nonenzymic oxidative stresses promote the generation of peroxide products (e.g., superoxide, H₂O₂, and ROS), causing an imbalance in oxidant-antioxidant systems in vivo. The accumulation of such products induces a direct toxicity in cells and tissues, in which XO, NOX, and NOS are primary oxidases related to IRI. Irisin exerts protective effects on IRI by activation of the antioxidant system and inhibition of the expression and activity of oxidases (see Table 1). However, little is known about the mechanisms that regulate irisin-mediated inhibition of IRI-related oxidative stress. Given that irisin regulates the three major oxidase systems and the antioxidant system, the following questions emerge: First, is the regulation of oxidant and antioxidant systems by irisin homogeneous in various tissues and affected by IRI? Second, what general features of these IRI-related disorders mediate their sensitivity to irisin regulation? Third, considering the relationship between NO, oxidases, and IRI, is the heterogeneous regulation for NO in IRI also mediated by irisin? Fourth, irisin might regulate oxidases and the components of the antioxidant system via multiple mechanisms. Are the protective effects of irisin and the existing therapies for IRI synergetic or redundant?

4.2. Mitochondrial Protection by Irisin during IRI. Irisin-mediated thermogenesis and energy expenditure are closely related to the biological functions of mitochondria, in which uncoupling proteins (UCPs) regulate mitochondrial functions within various tissues [95, 99, 103, 104]. Mitochondrial dysfunction plays a critical role during pulmonary IRI. The

| Organs                        | Effects on IRI | Mechanisms involving irisin | Ref.   |
|-------------------------------|----------------|-----------------------------|--------|
| Cerebral IRI                  | Inflammation↓  | NLRP3 pathway               | [119]  |
|                               | Inflammation↓  | Notch pathway               | [120, 121] |
|                               | O₂↑, MDAs↓, 4-HNEs↓ | PKB and ERK pathways       | [97]   |
|                               | PGC1-α↑, TFAM↑ | Mitochondrial biogenesis    | [113]  |
| Flap revascularization        | Endothelial cell proliferation | antioxidative stress         | [102]  |
|                               | HDAC4 degradation↓ | HDAC sumoylation          | [108]  |
|                               | MITOL↑         | Anti-ER stress              | [122]  |
|                               | NOX↓           | Antioxidative stress        | [100]  |
|                               | Opa1↑          | Mitochondrial fusion        | [42]   |
|                               | Opa1↑          | Mitophagy                   | [76, 111] |
| Heart IRI                    | PGC1-α deacetylation | AMPK pathway               | [126, 127] |
|                               | Proangiogenic function | ERK pathway            | [129]  |
|                               | ROS↓, SOD↑     | Antioxidative stress        | [95, 96] |
|                               | SOD2↑, calcium overload↓ | Mitochondrial permeability | [95]   |
|                               | SOD2 localization | Mitochondrial permeability | [96]   |
|                               | UCP3↑          | Anti-mtROS                  | [107]  |
|                               | Drp1↓, Fis1↓   | Mitochondrial fission       | [68]   |
|                               | PGC1-α↑, TFAM↑ | Mitochondrial biogenesis    | [68]   |
| Hepatic IRI                   | Kindlin-2↑     | Anti-ER stress              | [125]  |
|                               | UCP2↑          | Anti-mtROS                  | [68]   |
| Hind limb IRI                | Inflammatory biomarkers↓ | Anti-inflammation           | [118]  |
|                               | Inflammation↓  | Anti-ER stress              | [99]   |
| Intestinal IRI               | MDAs↓, 4-HNEs↓, GPXs↑ | Antioxidative stress        | [98]   |
|                               | SOD↓, GPXs↑, XO↑ | Antioxidative stress        | [99]   |
| Pulmonary IRI                | UCP2↑          | Anti-mtROS                  | [105]  |
|                               | Inflammation↓  | Anti-ER stress              | [117]  |
| Renal IRI                    | Inflammation↓  | P53 inactivation            | [117]  |
|                               | UCP2↑          | Anti-mtROS                  | [106]  |

AMPK: adenosine 5′-monophosphate-activated protein kinase; Drp1: dynamin-related protein 1; ERK: extracellular-regulated protein kinases; ER stress: endoplasmic reticulum stress; Fis1: fission protein 1; GPXs: glutathione peroxidases; HDAC: histone deacetylases; 4-HNEs: 4-hydroxy-2-nonenals; IRI: ischemia-reperfusion injury; MDAs: malondialdehydes; MMP: mitochondrial membrane potential; mPTP: mitochondrial permeability transition pore; mtROS: mitochondrial reactive oxygen species; NOX: NADPH oxidase; O₂: superoxide; Opal: optic atrophy 1; PGC1-α: PPAR-γ coactivator-1α; PKB: protein kinase B; SOD: superoxide dismutase; TFAM: target mitochondrial transcription factor A; UCPs: uncoupling proteins; XO: xanthine oxidase; ↓: decrease; ↑: increase; /: “or”.

Table 1: The effects and mechanisms of irisin during ischemia-reperfusion injury.
interaction between irisin and UCP2 inhibits decomposition of UCP2 after pulmonary IRI, reducing lung damage due to mitochondrial dysfunction derived-ROS [105]. Similarly, irisin is protective in hepatic and renal models of IRI through the upregulation of UCP2 [68, 106]. Decreased UCP2 levels result in direct damage to the mitochondrial DNA by ROS, leading to mitochondrial dysfunction and cell death. Ischemic postconditioning may exert mitochondrial protection by affecting the level of UCP3 and irisin during myocardial IRI [107]. Moreover, irisin plays a role in modifying the mitochondrial membrane potential (MMP) and mPTP openings. According to reports about MMP and mPTP, irisin plays a role in modifying the upregulation of UCP2 [68, 106]. Decreased UCP2 levels after pulmonary IRI, reducing lung damage due to abnormal mitochondrial membrane potential and permeability, and unbalanced mitochondrial dynamics mediate mitochondrial dysfunction and contribute to irreversible cell death, thereby exacerbating IRI. Except for the antioxidant effects produced by the interplay between irisin and UCPs, irisin suppresses mitochondrial permeability by reducing mPTP opening. Irisin is also involved in regulating the expression of mitochondrial quality control-related molecules. All of abovementioned effects can significantly delay hypoxia or ischemia-induced mitochondrial dysfunction (see Table 1). Although numerous papers have been published about the effects of irisin on mitochondrial dysfunction during IRI, important questions remain: How does irisin regulate target molecules involved in IRI-induced mitochondrial dysfunction? Does irisin have an effect on reversing abnormal glucolipid metabolism in mitochondria caused by IRI? Does irisin protect against different types of cell death (e.g., apoptosis, necrosis, and ferroptosis) induced by mitochondrial dysfunction? Does excessive irisin trigger mitochondrial overdrive and noxious metabolite?

4.3. Anti-Inflammation of Irisin in IRI. The potential role of irisin as an anti-inflammation molecule has garnered widespread attention. The expression and activity of proinflammatory cytokines (e.g., TNF-α and interleukin-6) are enhanced as a result of obesity. They induce phosphorylation of inflammation-related nuclear factor kappa B (NF-κB) and secrete proinflammatory “recruiting-related monocyte chemotactic protein 1” (MCP-1) [114]. Irisin suppresses the aforementioned proinflammatory response in a dose-dependent manner, while it also promotes phenotypic transformation of macrophages to synergistically exert an anti-inflammatory effect [114]. In a mouse model of atherosclerosis, irisin impedes the infiltration of inflammatory cells including T lymphocytes and macrophages into the atherosclerotic lesion [75]. Moreover, irisin upregulates the expression of microRNA126 to mitigate the adhesion of monocytes to the vascular endothelium [115]. Therefore, irisin inhibits the initial activation of the immune response under several pathological states. In addition, irisin blunts the activity of neutrophil elastase and fuels antioxidant function, contributing to the inhibition of the inflammatory cascade. Various studies have shown that irisin enhances the expression of Nrf2 in mice with chronic obstructive pulmonary disease (COPD). On one hand, Nrf2 balances the protease-antiprotease system in favor of suppressing COPD-induced emphysema. On the other hand, Nrf2 induces the expression of antioxidant enzymes and decreases the level of proinflammatory cytokines (e.g., interleukin-6 and interleukin-1β), which delays disease progression [116].

In summary, ETC-related mitochondrial oxidative stress, abnormal mitochondrial membrane potential and permeability, and unbalanced mitochondrial dynamics mediate mitochondrial dysfunction and contribute to irreversible cell death, thereby exacerbating IRI. Except for the antioxidant effects produced by the interplay between irisin and UCPs, irisin suppresses mitochondrial permeability by reducing mPTP opening. Irisin is also involved in regulating the expression of mitochondrial quality control-related molecules. All of abovementioned effects can significantly delay hypoxia or ischemia-induced mitochondrial dysfunction (see Table 1). Although numerous papers have been published about the effects of irisin on mitochondrial dysfunction during IRI, important questions remain: How does irisin regulate target molecules involved in IRI-induced mitochondrial dysfunction? Does irisin have an effect on reversing abnormal glucolipid metabolism in mitochondria caused by IRI? Does irisin protect against different types of cell death (e.g., apoptosis, necrosis, and ferroptosis) induced by mitochondrial dysfunction? Does excessive irisin trigger mitochondrial overdrive and noxious metabolite?
inflammation and tubular cell apoptosis [117]. Similarly, Kucuk et al. [118] showed that administration of irisin suppresses inflammation in a murine model of hind limb IRI evidenced by improvement of inflammatory biomarkers. Using oxygen-glucose deprivation (OGD) to mimic ischemic states in vitro, the expression of NOD-like receptor family, pyrin domain-containing 3 (NLRP3), and its downstream molecules (e.g., interleukin-1β and interleukin-18) were increased in a time-dependent manner. The administration of irisin reversed the activation of the NLRP3 inflammatory pathway induced by OGD, and as such exerted a neuroprotective effect in an ischemic stroke model [119]. Irisin can also stimulate the Notch signaling pathway to inhibit activity of microglial cells and inflammation, which also exerts a neuroprotective effect following cerebral IRI [120]. In addition, toll-like receptor-related pathways and NF-κB activation induced mechanisms also play roles in protecting against neuronal injury and neurofunctional deficits after cerebral IRI [121].

As mentioned above, the activation of an initial inflammatory response and the subsequent amplification of inflammatory cascades during IRI can be ameliorated by irisin. Under ischemia and hypoxia, irisin inhibits the activation of
proinflammatory pathways and the expression of inflammatory factors in order to protect against inflammatory injury following IRI (see Table 1). Current research mainly concentrates on verifying the anti-inflammatory effects of irisin during IRI, but the exploration of specific targets of irisin during the two inflammatory stages is lacking. Neutrophils are regarded as a central cell type for IRI-induced inflammation, but the effects of irisin on neutrophil haptotaxis, protease release, and oxidative burst during IRI remains unclear. In addition, the upregulated expression of antioxidation response element (e.g., Nrf2) mediated by irisin has an effect on suppressing the expression of proinflammatory genes in hypoxic disease as well as in IRI [98, 116]. Consequently, it is reasonable to study both the antioxidant and anti-inflammatory effects of Nrf2 and how they contribute to the regulation of multiple targets by irisin.

4.4. The Regulatory Signaling between Irisin and IRI. The expression of myocardial ubiquitin ligase MITOL is upregulated after administration of irisin, and it can exert a cardioprotective effect against myocardial IRI. MITOL is a vital molecule that regulates the interaction between the endoplasmic reticulum (ER) and mitochondria. During myocardial IRI, irisin increases the expression of MITOL, which in turn causes the "inositol-requiring kinase enzyme 1α" (IRE1α), a significant sensor in ER stress, to be ubiquitylated by MITOL [122]. Such an anti-ER stress effect of irisin further exerts cardioprotection via inhibition of the expression of apoptosis-related proteins. Moreover, upregulated MITOL exerts antioxidative stress effects and regulates mitochondrial dynamics following myocardial IRI. With respect to the anti-ER stress effect of irisin, there have been reports that irisin inhibits ER stress and oxidative stress by upregulating the level of GPX4, a phospholipid hydroperoxidase that protects against cell membrane lipid peroxidation. Increased GPX4 levels protect against ischemia-reperfusion-induced acute kidney injury [123]. ER stress and mitochondrial dysfunction also play significant roles in severe acute pancreatitis, where both effects can be suppressed by irisin [124]. Moreover, exogenous irisin inhibits ER stress and oxidative stress, and it exerts protection against mitochondrial dysfunction by improving the intestinal epithelial barrier function following intestinal IRI though the integrin αV/β5-AMPK-UCP 2 pathway [99]. Kindlin-2 can interact with the irisin receptor integrin αV/β5, and this interaction improves oxidative stress and mitochondrial dysfunction and inhibits ER stress and inflammation, in a mouse model of nonalcoholic fatty liver disease [125].

The adenosine 5'-monophosphate-activated protein kinase (AMPK) signaling pathway is another key hub for connecting irisin and IRI. In diabetic FND5C5 knockout mice subjected to myocardial IRI, cardiac function was found to have deteriorated, and the ischemic area was enlarged due to impaired AMPK signaling. In terms of the mechanisms, irisin promotes AMPK signaling to improve glucose uptake and glycolysis during ischemia; furthermore, the activity of AMPK signaling triggered by irisin alleviates mitochondrial dysfunction [126]. In addition, AMPK promotes deacetylation of PGC1-α and then increases the expression of irisin, which relieves oxidative stress during cardiac IRI (e.g., cardiorenal syndrome). Notably, aerobic exercise or genetic knockout of lysocardiolipin acyltransferase 1 (ALCAT1) activates the aforementioned AMPK-PGC1-α-irisin signaling cascade, thereby alleviating the oxidative stress-triggered mitochondrial dysfunction and cell apoptosis in kidneys of mice with myocardial infarction [127].

Ubiquitination and deacetylation are also involved in the protective effects of irisin for IRI. Small ubiquitin-like modification (SUMO) participates in rescuing hypoxia/reoxygenation-mediated injury after administration of irisin [108]. Irisin can induce sumoylation of histone deacetylases (HDAC), mitigating HDAC4-induced mitochondrial dysfunction during hypoxia/reoxygenation-mediated injury [108]. At the translational level, irisin promotes the upregulation of brain-derived neurotrophic factor (BDNF) and downregulation of matrix metalloproteinase-9 (MMP9), both of which exert a neuroprotective effect in cerebral IRI [128]. Furthermore, irisin has proangiogenic effects during heart IRI as a result of activating ERK pathway [129]. Finally, irisin-mediated inactivation of tumor suppressor gene P53 also curtails inflammation following renal IRI [117].

The regulatory signaling pathways mentioned above mediate the effects of irisin during IRI in various aspects and provide clues for new ways to supplement IRI therapeutic strategies (see Table 1). Irisin seems to be a pharmacologically tractable node for counteracting IRI, and the role of irisin in modulating intracellular metabolism under different stresses has garnered widespread attention. To date, studies on the therapeutic effects of irisin during IRI remains scarce, and little is known about the regulation of irisin at the transcriptional level. For example, nothing is known yet about the potential regulation of irisin by noncoding RNA [130]. The exact mechanisms responsible for the effects of irisin on IRI are far from being completely understood. The different roles of the same molecule in various pathways require further investigation, so that the full extent of irisin treatment against IRI-related diseases can be understood at the mechanistic level.

5. Discussion and Future Directions

Ischemia-reperfusion injury (IRI) is a central feature of various disease processes, and it can be a primary cause for high morbidity and case fatality rates. Oxidative stress, mitochondrial dysfunction, and an inflammatory response are crucial elements of the pathogenesis of IRI. Irisin is a myokine that was discovered in 2012, which is produced by cleavage of the c-terminus of FND5C5 [65]. The antioxidant and anti-inflammatory effects as well as the mitochondrial protective effects of irisin have been demonstrated in various studies. These effects of irisin overlap with the pathogenic mechanisms of IRI (see Figure 3) In this review article, we first focused on the pathogenesis of IRI, dissecting the inherent mechanisms of IRI including oxidative stress, mitochondrial dysfunction, and the inflammatory response, as well as the main molecules involved in those pathways. Next, we summarized how irisin modulates IRI through its effects on oxidative stress, mitochondrial dysfunction, and inflammation.
The purpose of this review was also to identify gaps in knowledge and to provide ideas for new research directions aimed at developing new therapeutic strategies with precision and multiple targets for the treatment of IRI. Future studies into the mechanistic effects of irisin can enable translational studies that can potentially be extended into clinical applications.

There are some gaps in our knowledge of irisin that need to be studied: (1) The effective targets and regulatory pathways are yet to be ascertained. (2) There is a gap between fundamental research studies and clinical studies in this area. (3) The technical difficulties in detecting irisin needs to be improved. Nevertheless, it appears that irisin has a great therapeutic potential based on IRI-related studies in recent years. Firstly, an abnormal concentration of irisin in plasma is regarded as a candidate biomarker for organ damage under pathological conditions (e.g., cardiovascular disease, metabolic disease, and tumor) [87, 131–133]. In light of this, we postulate that irisin could serve as a biomarker for IRI, for the diagnosis for organ damage, for the assessment of the severity of the injury, or for the potential protective effect of a treatment. Second, it is unclear whether the administration of exogenous irisin will cooperate with existing treatments for IRI-related disorders. Moreover, it would be important to assess the potential benefits of a combined treatment involving irisin and remote ischemic preconditioning. In conclusion, the current literature suggests that irisin holds great promise for the treatment if IRI. Technological improvements and extensive experimental and clinical research are needed to accelerate the potential development of an irisin-based treatment for IRI-related disorders.

Abbreviations

ALCAT1: Aerobic exercise or genetic knockout of lysocardiopin acyltransferase 1
AMPK: Adenosine 5’-monophosphate-activated protein kinase
ATP: Adenosine triphosphate
BDNF: Brain-derived neurotrophic factor
BH4: Tetrahydrobiopterin
CAD: Coronary artery disease
COPD: Chronic obstructive pulmonary disease
CoQ: Coenzyme Q
DAMPs: Damage-associated molecular patterns
Drp1: Dynamin-related protein 1
ER: Endoplasmic reticulum
ERK: Extracellular-regulated protein kinases
ETC: Electron transport chain
FAD: Flavin adenine dinucleotide
Fis1: Fission protein 1
FMN: Flavin mononucleotide
FNDC5: Fibronectin type III domain-containing protein 5
GPXs: Glutathione peroxidases
HDAC: Histone deacetylases
4-HNEs: 4-Hydroxy-2-nonenals
H2O2: Hydrogen peroxide
HIF-1α: Hypoxia-inducible factor-1α
HOCl: Hypochlorous acid
IRE1α: Inositol-requiring kinase enzyme 1α
IRI: Ischemia-reperfusion injury
L-Arg: L-arginine
L-Cit: L-citrulline
MCP-1: Monocyte chemotactic protein 1
MDAs: Malondialdehydes
MMP: Mitochondrial membrane potential
MMP9: Matrix metalloproteinase-9
mPTP: Mitochondrial permeability transition pore
mtROS: Mitochondrial ROS
NADPH: Nicotinamide adenine dinucleotide phosphate
NF-κB: Nuclear factor kappa B
NLRP3: NOD-like receptor family, pyrin domain-containing 3
NO: Nitric oxide
NOS: Nitric oxide synthase
NOX: NADPH oxidase
Nrf2: Nuclear factor E2-related factor 2
O2−: Oxygen
O2•−: Superoxide
OCI: Hypochlorite
OGD: Oxygen-glucose deprivation
OCl−: Hypochlorite
O2: Oxygen
OCl−: Hypochlorous acid
Opa1: Optic atrophy 1
PGC1-α: PPAR-c coactivator-1α
PKB: Protein kinase B
PPAR: Peroxisome proliferator-activated receptor
RET: Reverse electron transport
ROS: Reactive oxygen
SCD: Sickle cell disease
SOD1: Superoxide dismutase 1
sRBC: Sickle red blood cells
SUMO: Small ubiquitin-like modification
TFAM: Mitochondrial transcription factor A
TNF-α: Tumor necrosis factor α
UCPs: Uncoupling proteins
XD: Xanthine dehydrogenase
XO: Xanthine oxidase.

Conflicts of Interest

The authors declare that there is no conflict of interest regarding the publication of this paper.

Authors’ Contributions

Yani Wang and Huibin Liu contributed equally to this work.

Acknowledgments

This work was supported by grants from the National Institutes of Health (Grant Nos. R01HL089598, R01HL147188, and R01HL153358 to X.W.), the National Natural Science Foundation of China (Grant Nos. 91739113 and 81971715 to J.W.T. and 81827806 to B.Y.), the National Key R&D Program of China (Grant No. 2016YFC1301100 to B.Y.), the Fok Ying-Tong Education Foundation for Young Teachers (171032 to J.W.T.), the Foundation of Guangxi Key Laboratory of Diabetic Systems Medicine (GKLCDSM-20200101-
References

[1] H. K. Eltzschig and T. Eckle, "Ischemia and reperfusion— from mechanism to translation," Nature Medicine, vol. 17, no. 11, pp. 1391–1401, 2011.

[2] D. N. Granger and P. R. Kvet tys, "Reperfusion injury and reactive oxygen species: the evolution of a concept," Redox Biology, vol. 6, pp. 524–551, 2015.

[3] H. Sies, "Oxidative stress: a concept in redox biology and medicine," Redox Biology, vol. 4, pp. 180–183, 2015.

[4] M. Y. Wu, G. T. Yang, W. T. Liao et al., "Current mechanistic concepts in ischemia and reperfusion injury," Cellular Physiology and Biochemistry, vol. 46, no. 4, pp. 1650–1667, 2018.

[5] T. Kalogeris, C. P. Baines, M. Krenz, and R. J. Korthuis, "Ischemia/reperfusion," Comprehensive Physiology, vol. 7, no. 1, pp. 113–170, 2016.

[6] O. N. Okafor, K. Farrington, and D. A. Gorog, "Allopurinol as a therapeutic option in cardiovascular disease," Pharmacology & Therapeutics, vol. 172, pp. 139–150, 2017.

[7] T. E. DeCourcey, D. Morgan, and V. V. Cherny, "The voltage dependence of NADPH oxidase reveals why phagocytes need proton channels," Nature, vol. 422, no. 6931, pp. 531–534, 2003.

[8] F. Magnani, S. Nenci, E. M. Fananas et al., "Crystal structures and atomic model of NADPH oxidase," Proceedings of the National Academy of Sciences of the United States of America, vol. 114, no. 26, pp. 6674–6679, 2017.

[9] T. M. Paravicini and R. M. Touyz, "NADPH oxidases, reactive oxygen species, and hypertension: clinical implications and therapeutic possibilities," Diabetes Care, vol. 31, Supplement 2, pp. S170–S180, 2008.

[10] M. Sedeek, R. Nasrallah, R. M. Touyz, and R. L. Hébert, "NADPH oxidases, reactive oxygen species, and the kidney: friend and foe," Journal of the American Society of Nephrology, vol. 24, no. 10, pp. 1512–1518, 2013.

[11] K. Bedard and K. H. Krause, "The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology," Physiological Reviews, vol. 87, no. 1, pp. 245–313, 2007.

[12] Z. M. Moghadam, P. Henneke, and J. Kolter, "From flies to men: ROS and the NADPH oxidase in phagocytes," Frontiers in Cell and Developmental Biology, vol. 9, 2021.

[13] B. Hassnania, P. Vandenabeele, and T. V. Berghé, "Targeting ferroptosis to iron out cancer," Cancer Cell, vol. 35, no. 6, pp. 830–849, 2019.

[14] H. PARK, J. CHUN, H. JUNG, C. CHOI, and Y. BAE, "Role of NADPH oxidase 4 in lipopolysaccharide-induced proinflammatory responses by human aortic endothelial cells," Cardiovascular Research, vol. 72, no. 3, pp. 447–455, 2006.

[15] P. A. Fraser, "The role of free radical generation in increasing cerebrovascular permeability," Free Radical Biology & Medicine, vol. 51, no. 5, pp. 967–977, 2011.

[16] M. Carlstrom, "Nitric oxide signalling in kidney regulation and cardiometabolic health," Nature Reviews Nephrology, vol. 17, no. 9, pp. 575–590, 2021.

[17] P. M. Vanhouotte, Y. Zhao, A. Xu, and S. W. S. Leung, "Thirty years of saying NO: sources, fate, actions, and misfortunes of the endothelium-derived vasodilator mediator," Circulation Research, vol. 119, no. 2, pp. 375–396, 2016.

[18] P. Sundd, M. T. Gladwin, and E. M. Novelli, "Pathophysiology of sickle cell disease," Annual Review of Pathology, vol. 14, no. 1, pp. 263–292, 2019.

[19] S. Moerdler and D. Manwani, "New insights into the pathophysiology and development of novel therapies for sickle cell disease," Hematology. American Society of Hematology. Education Program, vol. 2018, no. 1, pp. 493–506, 2018.

[20] E. J. Lesnfsky, Q. Chen, B. Tandler, and C. L. Hoppel, "Mitochondrial dysfunction and myocardial ischemia-reperfusion: implications for novel therapies," Annual Review of Pharmacology and Toxicology, vol. 57, no. 1, pp. 535–565, 2017.

[21] J. Hirst, "Mitochondrial complex I," Annual Review of Biochemistry, vol. 82, no. 1, pp. 551–575, 2013.

[22] A. S. Milliken, C. A. Kulkarni, and P. S. Brookes, "Acid enhancement of ROS generation by complex-I reverse electron transport is balanced by acid inhibition of complex-II: relevance for tissue reperfusion injury," Redox Biology, vol. 37, article 101733, 2020.

[23] E. T. Chouchani, V. R. Pell, A. M. James et al., "A unifying mechanism for mitochondrial superoxide production during ischemia-reperfusion injury," Cell Metabolism, vol. 23, no. 2, pp. 254–263, 2016.

[24] Y. R. Chen and J. L. Zweier, "Cardiac mitochondria and reactive oxygen species generation," Circulation Research, vol. 114, no. 3, pp. 524–537, 2014.

[25] S. Cadenas, "ROS and redox signaling in myocardial ischemia-reperfusion injury and cardioprotection," Free Radical Biology & Medicine, vol. 117, pp. 76–89, 2018.

[26] R. Becerra, B. Román, M. N. Di Carlo et al., "Reversible redox modifications of cytochrome oxidase ameliorate ventricular arrhythmias in the ischemic-reperfused heart," American Journal of Physiology. Heart and Circulatory Physiology, vol. 311, no. 3, pp. 1713–1724, 2016.

[27] M. N. Di Carlo, M. Said, H. Ling et al., "CaMKII-dependent phosphorylation of cardiac cytochrome oxidase receptors regulates cell death in cardiac ischemia/reperfusion injury," Journal of Molecular and Cellular Cardiology, vol. 74, pp. 274–283, 2014.

[28] A. Xu, K. Szczepanek, Y. Hu, E. J. Lesnfsky, and Q. Chen, "Cardioprotection by modulation of mitochondrial respiration during ischemia-reperfusion: role of apoptosis-inducing factor," Biochemical and Biophysical Research Communications, vol. 435, no. 4, pp. 627–633, 2013.

[29] Z. Chen, Y. Liang, X. Feng et al., "Vitamin-B12-conjugated PLGA-PEG nanoparticles incorporating miR-532-3p induce mitochondrial damage by targeting apoptosis repressor with caspase recruitment domain (ARC) on CD320-overexpressed gastric cancer," Materials Science and Engineering C, vol. 120, p. 111722, 2021.

[30] B. Cho, H. M. Cho, Y. Jo et al., "Constriction of the mitochondrial inner compartment is a priming event for mitochondrial division," Nature Communications, vol. 8, no. 1, 2017.

[31] J. T. Cribbs and S. Strack, "Reversible phosphorylation of Drp1 by cyclic AMP-dependent protein kinase and calcineurin regulates mitochondrial fission and cell death," EMBO Reports, vol. 8, no. 10, pp. 939–944, 2007.

[32] K. J. De Vos, V. J. Allan, A. J. Grierson, and M. P. Sheetz, "Mitochondrial function and actin regulate dynamin-related..."
protein 1-dependent mitochondrial fission,” Current Biology, vol. 15, no. 7, pp. 678–683, 2005.

[33] C. S. Palmer, L. D. Osellame, D. Laine, O. S. Koutsopoulos, A. E. Frazier, and M. T. Ryan, “MiD49 and MiD51, new components of the mitochondrial fission machinery,” EMBO Reports, vol. 12, no. 6, pp. 565–573, 2011.

[34] L. D. Osellame, A. P. Singh, D. A. Stroud et al., “Cooperative and independent roles of the Drp1 adaptors Mff, MiD49 and MiD51 in mitochondrial fission,” Journal of Cell Science, vol. 129, no. 11, pp. 2170–2181, 2016.

[35] K. S. Dimmer and L. Scorrano, “(De)constructing mitochondria: what for?,” Physiology (Bethesda), vol. 21, pp. 233–241, 2006.

[36] M. Ding, C. Liu, R. Shi et al., “Mitochondrial fusion promoter restores mitochondrial dynamics balance and ameliorates diabetic cardiomyopathy in an optic atrophy 1-dependent way,” Acta Physiologica, vol. 229, no. 1, p. e13428, 2020.

[37] A. R. Anzell, R. Maizy, K. Przyklenk, and T. H. Sanderson, “Mitochondrial quality control and disease: insights into ischemia-reperfusion injury,” Molecular Neurobiology, vol. 55, no. 3, pp. 2547–2564, 2018.

[38] H. Zhou, J. Wang, P. Zhu et al., “NR4A1 aggravates the cardiac microvascular ischemia reperfusion injury through suppressing FUNDC1-mediated mitophagy and promoting Mff-required mitochondrial fission by CK2α,” Basic Research in Cardiology, vol. 113, no. 4, p. 23, 2018.

[39] F. Cacciapaglia, E. Salvatorelli, G. Minotti, A. Afeltra, and P. Menna, “Low level tumor necrosis factor-alpha protects cardiomyocytes against high level tumor necrosis factor-alpha: brief insight into a beneficial paradox,” Cardiovascular Toxicology, vol. 14, no. 4, pp. 387–392, 2014.

[40] W. W. Sharp, Y. H. Fang, M. Han et al., “Dynamin-related protein 1 (Drp1)-mediated diastolic dysfunction in myocardial ischemia-reperfusion injury: therapeutic benefits of Drp1 inhibition to reduce mitochondrial fission,” The FASEB Journal, vol. 28, no. 1, pp. 316–326, 2014.

[41] K. Zhang, H. Li, and Z. Song, “Membrane depolarization activates the mitochondrial protease OMA1 by stimulating self-cleavage,” EMBO Reports, vol. 15, no. 5, pp. 576–585, 2014.

[42] J. Nan, W. Zhu, M. S. Rahman et al., “Molecular regulation of mitochondrial dynamics in cardiac disease,” Biochim Biophys Acta Mol Cell Res, vol. 1864, no. 7, pp. 1260–1273, 2017.

[43] M. Song and G. W. Dorn 2nd, “Mitofusion: noncanonical functioning of dynamism factors in static mitochondria of the heart,” Cell Metabolism, vol. 21, no. 2, pp. 195–205, 2015.

[44] K.-L. Lin, S.-D. Chen, K.-J. Lin et al., “Quality matters? The involvement of mitochondrial quality control in cardiovascular disease,” Frontiers in Cell and Developmental Biology, vol. 9, 2021.

[45] Y. Zhao, G. Huang, S. Chen, Y. Gou, Z. Dong, and X. Zhang, “Homocysteine aggravates cortical neural cell injury through neuronal autophagy overactivation following rat cerebral ischemia-reperfusion,” International Journal of Molecular Sciences, vol. 17, no. 8, p. 1196, 2016.

[46] Z. Zeng, H.-M. Liu, Y.-Y. Zhang et al., “Aggravated intestinal ischemia-reperfusion injury is associated with activated mitochondrial autophagy in a mouse model of diabetes,” Molecular Medicine Reports, vol. 22, no. 3, pp. 1892–1900, 2020.

[47] C. Yi, L. Si, J. Xu, J. Yang, Q. Wang, and X. Wang, “Effect and mechanism of asiatic acid on autophagy in myocardial ischemia-reperfusion injury in vivo and in vitro,” Experimental and Therapeutic Medicine, vol. 20, no. 5, p. 54, 2020.

[48] Y. Maruyama, M. Araki, K. Kidokoro et al., “Evaluation of neutrophil dynamics change by protective effect of tadalafil after renal ischemia/reperfusion using in vivo real-time imaging,” Transplantation, vol. Publish Ahead of Print, 2021.

[49] J. Zhang, Q. Li, Y. R. Zou et al., “HMGB1-TLR4-IL-17A axis accelerates renal ischemia-reperfusion injury via the recruitment and migration of neutrophils,” Int Immunopharmacol, vol. 94, article 107433, 2021.

[50] T. H. C. Oliveira, P. E. Marques, P. Proost, and M. M. M. Teixeira, “Neutrophils: a cornerstone of liver ischemia and reperfusion injury,” Laboratory Investigation, vol. 98, no. 1, pp. 51–62, 2018.

[51] I. Rink, J. Rink, D. Helmer, D. Sachs, and K. Schmitz, “A haptotaxis assay for leukocytes based on surface-bound chemokine gradients,” Journal of Immunology, vol. 194, no. 11, pp. 5549–5558, 2015.

[52] D. H. Adams, C. Ju, S. K. Ramaiah, J. Uetrecht, and H. Jaeschke, “Mechanisms of immune-mediated liver injury,” Toxicological Sciences, vol. 115, no. 2, pp. 307–321, 2010.

[53] W. Y. Lee and P. Kubes, “Leukocyte adhesion in the liver: distinct adhesion paradigm from other organs,” Journal of Hepatology, vol. 48, no. 3, pp. 504–512, 2008.

[54] T. F. Lu, T. H. Yang, C. P. Zhong et al., “Dual effect of hepatic macrophages on liver ischemia and reperfusion injury during liver transplantation,” Immune Network, vol. 18, no. 3, article e24, 2018.

[55] R. F. van Golen, T. M. van Gulik, and M. Heger, “The sterile immune response during hepatic ischemia/reperfusion,” Cytokine & Growth Factor Reviews, vol. 23, no. 3, pp. 69–84, 2012.

[56] S. Sakai, H. Tajima, T. Miyashita et al., “Sivelestat sodium hydrate inhibits neutrophil migration to the vessel wall and suppresses hepatic ischemia-reperfusion injury,” Digestive Diseases and Sciences, vol. 59, no. 4, pp. 787–794, 2014.

[57] A. Kato, M. J. Edwards, and A. B. Lentsch, “Gene deletion of NF-κB p50 does not alter the hepatic inflammatory response to ischemia/reperfusion,” Journal of Hepatology, vol. 37, no. 1, pp. 48–55, 2002.

[58] K. E. Barletta, K. Ley, and B. Mehrad, “Regulation of neutrophil function by adenosine,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 32, no. 4, pp. 856–864, 2012.

[59] B. N. Cronstein, S. B. Kramer, G. Weissmann, and R. Hirschhorn, “Adenosine: a physiological modulator of superoxide anion generation by human neutrophils,” The Journal of Experimental Medicine, vol. 158, no. 4, pp. 1160–1177, 1983.

[60] R. Polanowska-Grabowska, K. Wallace, J. J. Field et al., “P-selectin-mediated platelet-neutrophil aggregate formation activates neutrophils in mouse and human sickle cell disease,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 30, no. 12, pp. 2392–2399, 2010.

[61] C. M. Lappas, Y. J. Day, M. A. Marshall, V. H. Engelhard, and J. Linden, “Adenosine A2A receptor activation reduces hepatic ischemia reperfusion injury by inhibiting CD1d-dependent NKT cell activation,” The Journal of Experimental Medicine, vol. 203, no. 12, pp. 2639–2648, 2006.
inflammation and injury in mice with sickle cell disease,” *Blood*, vol. 116, no. 23, pp. 5010–5020, 2010.

[63] N. Perakakis, G. A. Triantafyllou, J. M. Fernández-Real et al., “Physiology and role of irisin in glucose homeostasis,” *Nature Reviews. Endocrinology*, vol. 13, no. 6, pp. 324–337, 2017.

[64] P. Puigserver, Z. Wu, C. W. Park, R. Graves, M. Wright, and B. M. Spiegelman, “A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis,” *Cell*, vol. 92, no. 6, pp. 829–839, 1998.

[65] P. Boström, J. Wu, M. P. Jedrychowski et al., “A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis,” *Nature*, vol. 481, no. 7382, pp. 463–468, 2012.

[66] H. Kim, C. D. Wrann, M. Jedrychowski et al., “Irisin mediates effects on bone and fat via αV integrin receptors,” *Cell*, vol. 175, no. 7, pp. 1756–1768.e17, 2018.

[67] S. Aydin, T. Kuloglu, S. Aydin et al., “Cardiac, skeletal muscle and serum irisin responses to with or without water exercise in young and old male rats: cardiac muscle produces more irisin than skeletal muscle,” *Peptides*, vol. 52, pp. 68–73, 2014.

[68] J. Bi, J. Zhang, Y. Ren et al., “Irisin alleviates liver ischemia-reperfusion injury by inhibiting excessive mitochondrial fission, promoting mitochondrial biogenesis and decreasing oxidative stress,” *Redox Biology*, vol. 20, pp. 296–306, 2019.

[69] M. Y. Ho and C. Y. Wang, “Role of irisin in myocardial infarction, heart failure, and cardiac hypertrophy,” *Cells*, vol. 10, no. 6, pp. 2103, 2021.

[70] Y. T. Zhao, J. Wang, N. Yano et al., “Irisin promotes cardiac progenitor cell-induced myocardial repair and functional improvement in infarcted heart,” *Journal of Cellular Physiology*, vol. 234, no. 2, pp. 1671–1681, 2019.

[71] J. Fu, Y. Han, J. Wang et al., “Irisin lowers blood pressure by improvement of endothelial dysfunction via AMPK-Akt-eNOS-NO pathway in the spontaneously hypertensive rat,” *Journal of the American Heart Association*, vol. 5, no. 11, 2016.

[72] A. I. Mazur-Bialy, “Irisin acts as a regulator of macrophages host defense,” *Life Sciences*, vol. 176, pp. 21–25, 2017.

[73] R. S. Hotchkiss, A. Strasser, J. E. McDunn, and P. E. Swanson, “Cell death,” *The New England Journal of Medicine*, vol. 361, no. 16, pp. 1570–1583, 2009.

[74] R. Li, X. Wang, S. Wu et al., “Irisin ameliorates angiotensin II-induced cardiomyocyte apoptosis through autophagy,” *Journal of Cellular Physiology*, vol. 234, no. 10, pp. 17578–17588, 2019.

[75] H. Askari, S. F. Rajani, M. Poorebrahim, H. Haghi-Aminjan, E. Raesi-Abdollahi, and M. Abdollahi, “A glance at the therapeutic potential of irisin against diseases involving inflammation, oxidative stress, and apoptosis: an introductory review,” *Pharmacological Research*, vol. 129, pp. 44–55, 2018.

[76] M. Pesce, P. Ballerini, T. Paolucci, I. Puca, M. H. Farzaei, and A. Patruno, “Irisin and Autophagy: First Update,” *International Journal of Molecular Sciences*, vol. 21, no. 20, p. 7587, 2020.

[77] R. Badalzadeh, M. Mohammadi, M. Najafi, N. Ahmadiasi, S. Farajinia, and H. Ebrahimi, “The additive effects of ischemic postconditioning and cyclosporine-A on nitric oxide activity and functions of diabetic myocardium injured by ischemia/reperfusion,” *Journal of Cardiovascular Pharmacology and Therapeutics*, vol. 17, no. 2, pp. 181–189, 2012.

[78] J. Bi, L. Yang, T. Wang et al., “Irisin improves autophagy of aged hepatocytes via increasing telomerase activity in liver injury,” *Oxidative Medicine and Cellular Longevity*, vol. 2020, Article ID 6946037, 2020.

[79] W. Guo, B. Zhang, and X. Wang, “Lower irisin levels in coronary artery disease: a meta-analysis,” *Minerva Endocrinologica*, vol. 45, no. 1, pp. 61–69, 2020.

[80] T. H. Efe, B. Açar, A. G. Ertem et al., “Serum irisin level can predict the severity of coronary artery disease in patients with stable angina,” *Korean Circulation Journal*, vol. 47, no. 1, pp. 44–49, 2017.

[81] Z. M. Khorasan, R. K. Bagheri, M. A. Yaghoubi et al., “The association between serum irisin levels and cardiovascular disease in diabetic patients,” *Diabetes and Metabolic Syndrome: Clinical Research and Reviews*, vol. 13, no. 1, pp. 786–790, 2019.

[82] I. C. Hsieh, M. Y. Ho, M. S. Wen et al., “Serum irisin levels are associated with adverse cardiovascular outcomes in patients with acute myocardial infarction,” *International Journal of Cardiology*, vol. 261, pp. 12–17, 2018.

[83] K. N. Aronis, M. Moreno, S. A. Polyzos et al., “Circulating irisin levels and coronary heart disease: association with future acute coronary syndrome and major adverse cardiovascular events,” *International Journal of Obesity*, vol. 39, no. 1, pp. 156–161, 2015.

[84] S. Shen, R. Gao, Y. Bei et al., “Serum irisin predicts mortality risk in acute heart failure patients,” *Cellular Physiology and Biochemistry*, vol. 42, no. 2, pp. 615–622, 2017.

[85] S. Wang, C. Fu, H. Wang et al., “Polymorphisms of the peroxisome proliferator-activated receptor-γ coactivator-1α gene are associated with hypertrophic cardiomyopathy and not with hypertension hypertrophy,” *Clinical Chemistry and Laboratory Medicine*, vol. 45, no. 8, pp. 962–967, 2007.

[86] E. A. E. Badr, R. G. Mostafa, S. M. Awad et al., “A pilot study on the relation between irisin single-nucleotide polymorphism and risk of myocardial infarction,” *Biochemistry and Biophysics Reports*, vol. 22, article 100742, 2020.

[87] S. Aydin, S. Aydin, M. A. Kobat et al., “Decreased saliva/serum irisin concentrations in the acute myocardial infarction promising for being a new candidate biomarker for diagnosis of this pathology,” *Peptides*, vol. 56, pp. 141–145, 2014.

[88] X. Liu, H. Mujahid, B. Rong et al., “Irisin inhibits high glucose-induced endothelial-to-mesenchymal transition and exerts a dose-dependent bidirectional effect on diabetic cardiomyopathy,” *Journal of Cellular and Molecular Medicine*, vol. 22, no. 2, pp. 808–822, 2018.

[89] M. Y. Ho, M. S. Wen, J. K. Yeh et al., “Excessive irisin increases oxidative stress and apoptosis in murine heart,” *Biochemical and Biophysical Research Communications*, vol. 503, no. 4, pp. 2493–2498, 2018.

[90] Q. Peng, R. Ding, X. Wang, P. Yang, F. Jiang, and X. Chen, “Effect of irisin on pressure overload-induced cardiac remodeling,” *Archives of Medical Research*, vol. 52, no. 2, pp. 182–190, 2021.

[91] K. Inoue, S. Fujie, N. Hasegawa et al., “Aerobic exercise training-induced irisin secretion is associated with the reduction of arterial stiffness via nitric oxide production in adults with obesity,” *Applied Physiology, Nutrition, and Metabolism*, vol. 45, no. 7, pp. 715–722, 2020.

[92] X. Deng, W. Huang, J. Peng et al., “Irisin alleviates advanced glycation end products-induced inflammation and
endothelial dysfunction via inhibiting ROS-NLRP3 inflammasome signaling,” *Inflammation*, vol. 41, no. 1, pp. 260–275, 2018.

[93] D. Zhu, H. Wang, J. Zhang et al., “Irisin improves endothelial function in type 2 diabetes through reducing oxidative/nitritive stresses,” *Journal of Molecular and Cellular Cardiology*, vol. 87, pp. 138–147, 2015.

[94] S. Aydin, T. Kuloglu, S. Aydin et al., “The effect of iloprost and sildenafil, alone and in combination, on myocardial ischaemia and nitric oxide and irisin levels,” *Cardiovascular Journal of Africa*, vol. 28, no. 6, pp. 389–396, 2017.

[95] H. Wang, Y. T. Zhao, S. Zhang et al., “Irisin plays a pivotal role to protect the heart against ischemia and reperfusion injury,” *Journal of Cellular Physiology*, vol. 232, no. 12, pp. 3775–3785, 2017.

[96] Z. Wang, K. Chen, Y. Han et al., “Irisin protects heart against ischemia-reperfusion injury through a SOD2-dependent mitochondria mechanism,” *Journal of Cardiovascular Pharmacology*, vol. 72, no. 6, pp. 259–269, 2018.

[97] D. J. Li, Y. H. Li, H. B. Yuan, L. F. Qu, and P. Wang, “The novel exercise-induced hormone irisin protects against neuronal injury via activation of the Akt and ERK1/2 signaling pathways and contributes to the neuroprotection of physical exercise in cerebral ischemia,” *Metabolism*, vol. 68, pp. 31–42, 2017.

[98] J. du, X. Fan, B. Yang, Y. Chen, K. X. Liu, and J. Zhou, “Irisin pretreatment ameliorates intestinal ischemia/reperfusion injury in mice through activation of the Nrf2 pathway,” *International Immunopharmacology*, vol. 73, pp. 225–235, 2019.

[99] J. Bi, J. Zhang, Y. Ren et al., “Irisin reverses intestinal epithelial barrier dysfunction during intestinal injury via binding to the integrin αVβ5 receptor,” *Journal of Cellular and Molecular Medicine*, vol. 24, no. 1, pp. 996–1009, 2020.

[100] K. Gul-Kahraman, M. Yilmaz-Bozoglan, and E. Sahna, “Physiological and pharmacological effects of melatonin on remote ischemic conditioning after myocardial ischemia-reperfusion injury in rats: role of Cybb, Fas, NfkB, Irisin signaling pathway,” *Journal of Pineal Research*, vol. 67, no. 2, article e12589, 2019.

[101] N. Sun, Y. Chen, Y. Fan et al., “Plasma irisin levels are associated with hemodynamic and clinical outcome in idiopathic pulmonary arterial hypertension patients,” *Internal and Emergency Medicine*, vol. 16, no. 3, pp. 625–632, 2021.

[102] G. Zhao, X. Zhang, P. Xu, J. Y. Mi, and Y. J. Rui, “The protective effect of irisin against ischemia-reperfusion injury after perforator flap grafting in rats,” *Injury*, vol. 49, no. 12, pp. 2147–2153, 2018.

[103] T. Tu, S. Yin, J. Pang et al., “Irisin contributes to neuroprotection by promoting mitochondrial biogenesis after experimental subarachnoid hemorrhage,” *Frontiers in Aging Neuroscience*, vol. 13, article 640215, 2021.

[104] F. S. Wang, C. W. Kuo, J. Y. Ko et al., “Irisin mitigates oxidative stress, chondrocyte dysfunction and osteoarthritis development through regulating mitochondrial integrity and autophagy,” *Antioxidants*, vol. 9, no. 9, p. 810, 2020.

[105] K. Chen, Z. Xu, Y. Liu et al., “Irisin protects mitochondria function during pulmonary ischemia/reperfusion injury,” *Science Translational Medicine*, vol. 9, no. 418, 2017.

[106] R. Zhang, J. Ji, X. Zhou, and R. Li, “Irisin pretreatment protects kidneys against acute kidney injury induced by ischemia/reperfusion via upregulating the expression of uncoupling protein 2,” *BioMed Research International*, vol. 2020, Article ID 6537371, 2020.

[107] G. Aslan, H. F. Gul, and A. Tektemur, “Ischemic postconditioning reduced myocardial ischemia-reperfusion injury: the roles of melatonin and uncoupling protein 3,” *Anatolian Journal of Cardiology*, vol. 23, no. 1, pp. 19–27, 2020.

[108] Y. T. Zhao, H. Wang, S. Zhang, J. du, S. Zhuang, and T. C. Zhao, “Irisin ameliorates hypoxia/reoxygenation-induced injury through modulation of histone deacetylase 4,” *PLoS One*, vol. 11, no. 11, article e0166182, 2016.

[109] E. Q. Toyama, S. Herzig, J. Courchet et al., “Metabolism. AMP-activated protein kinase mediates mitochondrial fission in response to energy stress,” *Science*, vol. 351, no. 6270, pp. 275–281, 2016.

[110] P. H. Reddy, “Inhibitors of mitochondrial fission as a therapeutic strategy for diseases with oxidative stress and mitochondrial dysfunction,” *Journal of Alzheimer’s Disease*, vol. 40, no. 2, pp. 245–256, 2014.

[111] T. Xin and C. Lu, “Irisin activates Opal1-induced mitophagy to protect cardiomyocytes against apoptosis following myocardial infarction,” *Aging (Albany NY)*, vol. 12, no. 5, pp. 4474–4488, 2020.

[112] W. He, P. Wang, Q. Chen, and C. Li, “Exercise enhances mitochondrial fission and mitophagy to improve myocardial following critical limb ischemia in elderly mice via the PGC1α/FNDC5/irisin pathway,” *Skeletal Muscle*, vol. 10, p. 1, 2020.

[113] L. Li, L. Xiao, Y. Hou et al., “Sestrin2 Silencing Exacerberates Cerebral Ischemia/Reperfusion Injury by Decreasing Mitochondrial Biogenesis through the AMPK/PGC-1α Pathway in Rats,” *Scientific Reports*, vol. 6, no. 1, 2016.

[114] A. Mazur-Bialy, J. Bilski, E. Pocheć, and T. Brzozowski, “New insight into the direct anti-inflammatory activity of a myokine irisin against proinflammatory activation of adipocytes. Implication for exercise in obesity,” *Journal of Physiology and Pharmacology*, vol. 68, no. 2, pp. 243–251, 2017.

[115] C. Cerutti, L. J. Edwards, H. E. De Vries, B. Sharrack, D. K. Male, and I. A. Romero, “MiR-126 and miR-126+ regulate shear-resistant firm leukocyte adhesion to human brain endothelium,” *Scientific reports*, vol. 7, article 45284, 2017.

[116] H. Kubo, K. Asai, K. Kojima et al., “Exercise ameliorates emphysema of cigarette smoke-induced COPD in mice through the exercise-axis,” *International Journal of Chronic Obstructive Pulmonary Disease*, vol. 14, pp. 2507–2516, 2019.

[117] Y. Liu, Y. Fu, Z. Liu et al., “Irisin is induced in renal ischemia-reperfusion to protect against tubular cell injury via suppressing p53,” *Biochimica et Biophysica Acta - Molecular Basis of Disease*, vol. 1866, no. 7, p. 165792, 2020.

[118] A. Küçüklü, Y. Polat, A. Kilçarslan et al., “Irisin protects against hind limb ischemia reperfusion injury,” *Drug Design, Development and Therapy*, vol. Volume 15, pp. 2507–2516, 2019.

[119] J. Peng, X. Deng, W. Huang et al., “Irisin protects against neuronal injury induced by oxygen-glucose deprivation in part depends on the inhibition of ROS-NLRP3 inflammatory signaling pathway,” *Molecular Immunology*, vol. 91, pp. 185–194, 2017.

[120] Z. Jin, P. Guo, X. Li, J. Ke, Y. Wang, and H. Wu, “Neuroprotective effects of irisin against cerebral ischemia/ reperfusion neurological damage via inhibiting ROS-NLRP3 inflammasome signaling,” *Inflammation*, vol. 41, no. 1, pp. 260–275, 2018.
injury via Notch signaling pathway,” *Biomedicine & Pharmacotherapy*, vol. 120, article 109452, 2019.

[121] Q. Yu, G. Li, Q. Ding et al., “Irisin protects brain against ischemia/reperfusion injury through suppressing TLR4/MyD88 pathway,” *Cerebrovascular Diseases*, vol. 49, no. 4, pp. 346–354, 2020.

[122] K. Takeda, S. Nagashima, I. Shiiba et al., “MITOL prevents ER stress-induced apoptosis by IRE1α ubiquitylation at ER-mitochondria contact sites,” *The EMBO Journal*, vol. 38, no. 15, article e100999, 2019.

[123] J. Zhang, J. Bi, Y. Ren et al., “Involvement of GPX4 in irisin’s protection against ischemia reperfusion-induced acute kidney injury,” *Journal of Cellular Physiology*, vol. 236, no. 2, pp. 931–945, 2021.

[124] Y. Ren, M. Qiu, J. Zhang et al., “Low serum irisin concentration is associated with poor outcomes in patients with acute pancreatitis, and irisin administration protects against experimental acute pancreatitis,” *Antioxidants & Redox Signaling*, vol. 31, no. 11, pp. 771–785, 2019.

[125] J. Zhang, Y. Ren, J. Bi et al., “Involvement of kindlin-2 in irisin’s protection against ischaemia reperfusion-induced liver injury in high-fat diet-fed mice,” *Journal of Cellular and Molecular Medicine*, vol. 24, no. 22, pp. 13081–13092, 2020.

[126] C. Xin, Z. Zhang, G. Gao et al., “Irisin attenuates myocardial ischemia/reperfusion injury and improves mitochondrial function through AMPK pathway in diabetic mice,” *Frontiers in Pharmacology*, vol. 11, article 565160, 2020.

[127] F. Wu, Z. Li, M. Cai et al., “Aerobic exercise alleviates oxidative stress-induced apoptosis in kidneys of myocardial infarction mice by inhibiting ALCAT1 and activating FNDC5/Irisin signaling pathway,” *Free Radical Biology & Medicine*, vol. 158, pp. 171–180, 2020.

[128] P. Guo, Z. Jin, H. Wu et al., “Effects of irisin on the dysfunction of blood–brain barrier in rats after focal cerebral ischaemia/reperfusion,” *Brain and Behavior: A Cognitive Neuroscience Perspective*, vol. 9, no. 10, article e01425, 2019.

[129] Q. Liao, S. Qu, L. X. Tang et al., “Irisin exerts a therapeutic effect against myocardial infarction via promoting angiogenesis,” *Acta Pharmacologica Sinica*, vol. 40, no. 10, pp. 1314–1321, 2019.

[130] V. Siebert, J. Allencherril, Y. Ye, X. H. T. Wehrens, and Y. Birnbaum, “The role of non-coding RNAs in ischemic myocardial reperfusion injury,” *Cardiovascular Drugs and Therapy*, vol. 33, no. 4, pp. 489–498, 2019.

[131] X. Provatopoulou, G. P. Georgiou, E. Kalogera et al., “Serum irisin levels are lower in patients with breast cancer: association with disease diagnosis and tumor characteristics,” *BMC Cancer*, vol. 15, no. 1, 2015.

[132] E. Emanuele, P. Minoretti, H. Pareja-Galeano, F. Sanchis-Gomar, N. Garatachea, and A. Lucia, “Serum irisin levels, precocious myocardial infarction, and healthy exceptional longevity,” *The American Journal of Medicine*, vol. 127, no. 9, pp. 888–890, 2014.

[133] T. Kuloğlu, S. Aydin, M. N. Eren et al., “Irisin: a potentially candidate marker for myocardial infarction,” *Peptides*, vol. 55, pp. 85–91, 2014.